Portal de investigación
A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
SAREPTA THERAPEUTICS INC
Cita
A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION). (SRP-9001-303). SAREPTA THERAPEUTICS INC. 2023IP:NURIA MUELAS GÓMEZ.